After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023. Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more. You can read all about the biggest diabetes stories […]
Ypsomed
Ypsomed, Mediq complete sale of DiaExpert
Ypsomed and Mediq announced today that they completed the sale of mail-order retailer for diabetes care DiaExpert. Germany-based DiaExpert specializes in insulin pump therapy. The companies previously announced the sale of DiaExpert in October. This sale allows Ypsomed to focus on the manufacture and sale of its own medical technologies. That focus continues to narrow […]
The 10 biggest diabetes tech stories from 2022
2022 represented a landmark year for next-generation diabetes tech. Here are the biggest stories from the past year. Some companies picked up major regulatory nods. Others experienced major regulatory setbacks. Partnerships were formed and ended, while mergers and acquisitions came and went. There were many stories to choose from in the world of diabetes tech, […]
Abbott FreeStyle Libre 3 links with automated insulin delivery system for use in Europe
Abbott (NYSE:ABT) today announced compatibility between its FreeStyle Libre 3 sensor and the mylife Loop from Ypsomed and CamDiab. Combined, the technologies create a smart, automated process for insulin delivery based on real-time glucose data. The companies launched their automated insulin delivery (AID) system in Germany. They intend to offer it in additional European countries […]
Eli Lilly discontinues Ypsomed collaboration to pursue its own U.S. insulin pump offering
Ypsomed announced today that Eli Lilly (NYSE:LLY) elected to stop their joint project to enter the U.S. insulin pump market. In November 2020, the companies entered into a commercialization agreement. The agreement entailed registering and commercializing Ypsomed’s YpsoPump under Lilly’s branding in the U.S. Ypsomed said that, over the past two years, it customized its […]
Ypsomed, CamDiab launch first automated insulin dosing system with Abbott FreeStyle Libre 3
Ypsomed announced that its mylife Loop now has authorization to work with the Abbott FreeStyle Libre 3 sensor in Germany. The Ypsomed mylife YpsoPump combines with the CamDiab mylife CamAPS FX algorithm and FreeStyle Libre 3. Together, they form an intelligent and automated insulin delivery (AID) system for people with type 1 diabetes. Users can […]
Ypsomed unveils new autoinjector
Ypsomed (SIX:YPSN) announced today that it developed a new autoinjector platform for liquid medications with volumes between 1.5 mL and 5.5 mL. Burgdorf, Switzerland-based Ypsomed built the YpsoMate 5.5 autoinjector on the established technology of the YpsoMate 2.25 Pro. The latest addition to the YpsoMate portfolio enables self-administration for larger-volume medications. These medications may treat […]
CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022
All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week. From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings. Here are five of the biggest stories to come out […]
Abbott, Camdiab, Ypsomed forge partnership for automated insulin delivery
Abbott (NYSE:ABT) announced today that it partnered with CamDiab and Ypsomed (SWX:YPSN) to produce an integrated automated insulin delivery (AID) system. The companies announced the partnership at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, Spain. It seeks to develop and commercialize the integrated AID system with an initial focus centered around […]
Ypsomed partners with CamDiab on smartphone-based automated insulin delivery
Ypsomed (SWX:YPSN) announced today that it partnered with CamDiab to collaborate on managing automated insulin delivery with a mobile app. The partnership aims to launch CamDiab’s CamAPS FX app for managing glucose levels via insulin pumps using an adaptive, hybrid closed-loop approach, for automated insulin delivery (AID) with Ypsomed’s MyLife YpsoPump system during the first […]
